Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experience

Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experience

Acquired Aplastic Anemia (AAA) is a rare disease involving primary bone marrow failure with consequent pancytopenia. The addition of the synthetic thrombopoietin-receptor agonist eltrombopag (ELT) to standard immunosuppression for the treatment of AAA has led to improvements in hemopoietic outcomes...

Full description

Bibliographic Details
Main Authors: Monica Carpenedo, Arianna Zappaterra, Lorenzo Del Castello, Beatrice Ferrari, Giulia Cotilli, Davide Paolo Bernasconi, Sara Pezzatti, Filippo Sacco, Lorenza Borin, Andrea Carrer, Luisa Verga, Filippo Brioschi
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Platelets
Subjects:
Acquired aplastic anemia
eltrombopag
immunosuppressive treatment
Online Access:https://www.tandfonline.com/doi/10.1080/09537104.2024.2415483

Internet

https://www.tandfonline.com/doi/10.1080/09537104.2024.2415483

Similar Items